Mobosetinib/Mobosetinib is a drug of several generations

Mobocertinib/Mobocertinib is a targeted anti-cancer drug that is a third-generation tyrosine kinase inhibitor (TKI). Its primary indication is the treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), particularly in patients who have progressed despite other treatments.

Compared with early first- and second-generationEGFR TKIs, such as erlotinib, gefitinib, afatinib, and dakotinib, moboxetinib has shown better efficacy in targeting specificEGFR mutations. Previous generations of drugs mainly targeted common EGFR mutations, such as EFGR exon 19 deletions or exon 21 substitutions (L858R), but had little or no clinical benefit for some non-small cell lung cancer patients carrying EGFR ex20ins. Mobosetinib is designed to effectively inhibit these drug-resistant mutations, thereby improving the therapeutic effect on tumors.

Mobosetinib was developed to overcomethe problem of EGFR TKI resistance. Clinical studies show that when treatingnon-small cell lung cancer patients with EGFR ex20ins, the overall response rate, progression-free survival time and overall survival index of mopotinib are significantly higher than those of previous EGFR TKI, and last longer, and have also achieved positive results in improving patients' quality of life. This makes the drug occupy an important position in the treatment of EGFR mutation-positive non-small cell lung cancer.

In addition, the administration of mobosertinib is relatively convenient, usually orally, which improves patient compliance. Its side effects are relatively controllable, and although adverse reactions such as rash, diarrhea, and abnormal liver function may still occur, most patients can tolerate these side effects. With the deepening understanding of EGFR mutations and their resistance mechanisms, moboxetinib may be used in combination with other emerging targeted drugs to further improve the therapeutic effect.